STOCKS TELEGRAPH

Tag: Jaguar

  • Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    After-hours trading on Wednesday saw a big recovery in Jaguar Health, Inc. (NASDAQ: JAGX) shares, which rose 8.33% to $3.01. The shares ended the trading day at $2.78, somewhat offsetting the company’s previous 14.06% regular-session drop. The recovery followed a virtual presentation at the Emerging Growth Conference by Lisa Conte, the founder and CEO of Jaguar Health, outlining the company’s recent accomplishments and future objectives.

    Advancing Canalevia-CA1 in Veterinary Medicine

    Recently, a field research was started by Jaguar Health’s Jaguar Animal Health subsidiary for Canalevia-CA1, an FDA-conditionally authorized medicine for canine chemotherapy-induced diarrhea (CID). This prospective, randomized, open-label clinical research, which involves dogs receiving chemotherapy across the United States, has seen the establishment of the company’s first study site. The research compares the results of the treatment and control groups in order to gather empirical data in favor of complete FDA clearance.

    Enhanced Indications and Strategic Objectives

    Securing complete FDA clearance for the CID indication and expanding its usage to treat general, non-infectious diarrhea in dogs are the two primary goals Jaguar Health is pursuing with Canalevia-CA1 (crofelemer delayed-release tablets). Discussions are underway with potential partners to support the development and global commercialization of crofelemer for this broader indication.

    This strategic expansion reflects the company’s recognition of a significant unmet need in veterinary medicine. Jaguar Health estimates approximately six million annual cases of acute and chronic canine diarrhea are seen by U.S. veterinarians, marking a considerable market opportunity.

    Regulatory Progress and Development Focus

    Jaguar Health has opened a new Investigational New Animal Drug (INAD) filing with the FDA’s Center for Veterinary Medicine to investigate the possibility of using crofelemer to treat dogs’ general, non-infectious diarrhea in order to assist these efforts. As a major driver of its continuous business growth activities, the firm has determined that establishing a strategic alliance for this program is a top goal for 2025.

  • Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Last Friday during the after-market session, there was a noticeable increase in the shares of Jaguar Health, Inc. (NASDAQ: JAGX) following the announcement of a noteworthy commercial endeavor. After a normal session fall of -9.75% that left the shares at $4.63, the stock had a comeback of 6.914% after hours, finishing at $4.95.

    Increasing Business Activity

    Jaguar Health (JAGX) shared intention to expand its commercial operations in its main area of expertise, cancer supportive care. Part of that plan, JAGX will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, which runs from May 31 to June 4. During the event, JAGX-division Napo Pharmaceuticals will have Gelclair on display at a booth. Jaguar Health recently obtained the in-license to sell Gelclair, a prescription drug authorized by the FDA for treating oral mucositis. The commercial launch of Gelclair is scheduled to commence in the third quarter of 2024 by Jaguar Health.

    Addressing Cancer Patients Issues

    JAGX’s Gelclair is a barrier-forming protective gel that coats the oral mucosa to assist control and lessen pain. It is used to treat sores in the mouth brought on by a number of illnesses, including oral mucositis and stomatitis. Gelclair does not hurt or function as a numbing agent like other treatments.

    Oral mucositis has a substantial financial impact; extra expenses for each patient with head and neck cancer surpass $17,000. With its handy, user-friendly, and clinically proven approach, Gelclair delivers patients quick and durable pain relief that enhances their ability to swallow, eat, drink, speak, and sleep.  It also reduces the necessity for parenteral feeding and opiate analgesics.

    Expanding Focus On Cancer Supportive Care

    At the ASCO Annual Meeting, Jaguar Health will promote awareness among oncologists about Gelclair and the company’s growing commitment to cancer supportive care. This commitment is further underscored by Jaguar Health’s five-year dedication to studying the prevention of cancer therapy-related diarrhea through the phase 3 OnTarget trial. This trial focuses on over 24 targeted cancer agents that have an incidence of more than 50% diarrhea, with top-line results expected soon.